SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Piffer OT - And Other Assorted Nuts
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jorj X Mckie who wrote (13612)1/11/2000 3:50:00 PM
From: Jerry Olson  Read Replies (1) of 63513
 
CLPA info....hope get an upgrade on this...

News Alert from Reuters via Quote.com
Topic: (NASDAQ:CLPA) ,
Quote.com News Item #12553825
Headline: Cell Pathways rises on colon polyp drug news

======================================================================
NEW YORK, Jan 11 (Reuters) - Shares of Cell Pathways Inc
(NASDAQ:CLPA) rose about 21 percent on Tuesday following news its
experimental drug Aptosyn for precancerous colon polyps may not
need to be evaluated by a federal advisory panel.
In afternoon trade, Cell Pathways was up 2-7/8 at 17-3/8 on
the Nasdaq in more than double its average daily trading
volume.
Earlier Tuesday, Cell Pathways said the Food and Drug
Administration told the Horsham, Pa.-based company that it
plans to evaluate Aptosyn's application for approval without
first going through an FDA advisory panel.
The move removes one more hurdle in the drug's approval
process.
Cell Pathways is seeking approval for Aptosyn for the
regression and prevention of precancerous colon polyps in
patients with the inherited disease, Familiar Adenomatous
Polyposis, or FAP.
FAP is a chronic indication that has no approved medical
treatment for the prevention of precancerous polyps.

Copyright 2000, Reuters News Service
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News